Lymphangiogenesis in kidney cancer:: Expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma

被引:23
作者
Birer, S. [1 ]
Herrmann, E. [1 ]
Koepke, T. [1 ]
Neumann, J. [2 ]
Eltze, E. [2 ]
Hertle, L. [1 ]
Wuelfing, C. [1 ]
机构
[1] Univ Hosp Munster, Dept Urol, D-48149 Munster, Germany
[2] Univ Hosp Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany
关键词
renal cell carcinoma; lymphangiogenesis; immunohistochemistry; clear cell; papillary; vascular endothelial growth factor;
D O I
10.3892/or_0000065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The vascular endothelial growth factors VEGF-C, VEGF-D and its receptor, VEGFR-3, are overexpressed in different malignancies and associated with lymph node metastasis and poor prognosis. We analysed these factors in clear cell (ccRCC) and papillary (pRCC) renal cell carcinoma (RCC). The results were correlated with various clinicopathological parameters (CPP). We constructed a tissue microarray with tumor samples of 135 (81%) ccRCC and 31 (19%) pRCC. After immunohistochemical staining using polyclonal antibodies for VEGF-C, VEGF-D and VEGFR-3, a semiquantitative analysis was performed to determine the levels of expression. The results were compared between the two subgroups and were correlated with CPP. In the two subgroups the expression of VEGF-C was significantly correlated with that of VEGF-D (p<0.001). There was an increased expression of VEGF-C in 11% of ccRCC and 36% of pRCC (p=0.002). VEGF-D expression was positive by means of analysis in 22% of ccRCC and 42% of pRCC (p=0.039). There was no significant difference regarding the expression of VEGFR-3 between the subgroups (44% ccRCC and 61 % pRCC, p=0.11). No correlation was found between the expression of the analysed parameters and CPP (TNM, grading, progression-free survival and overall survival) in either the entire group or in the two subgroups. In summary, ccRCC and pRCC show a different expression pattern of the analysed lymphangiogenic factors. Further studies are necessary to confirm these results and to determine whether the VEGF-C/VEGF-D/VEGFR-3-axis can play a role as a prognostic tool or a target for therapeutic intervention in renal cell carcinoma.
引用
收藏
页码:721 / 725
页数:5
相关论文
共 22 条
[1]   Targeting lymphangiogenesis to prevent tumour metastasis [J].
Achen, M. G. ;
Mann, G. B. ;
Stacker, S. A. .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1355-1360
[2]  
AISHIMA S, MOD PATHOL IN PRESS
[3]   Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues [J].
Bando, H ;
Brokelmann, M ;
Toi, M ;
Alitalo, K ;
Sleeman, JP ;
Sipos, B ;
Gröne, HJ ;
Weich, HA .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) :184-191
[4]   Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0):: The impact of aggressive surgical resection on patient outcome [J].
Canfield, SE ;
Kamat, AM ;
Sánchez-Ortiz, RF ;
Detry, M ;
Swanson, DA ;
Wood, CG .
JOURNAL OF UROLOGY, 2006, 175 (03) :864-869
[5]   Rising incidence of renal cell cancer in the United States [J].
Chow, WH ;
Devesa, SS ;
Warren, JL ;
Fraumeni, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1628-1631
[6]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[7]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[8]  
Gunningham SP, 2001, CANCER RES, V61, P3206
[9]   Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].
Hudes, Gary ;
Carducci, Michael ;
Tomczak, Piotr ;
Dutcher, Janice ;
Figlin, Robert ;
Kapoor, Anil ;
Staroslawska, Elzbieta ;
Sosman, Jeffrey ;
McDermott, David ;
Bodrogi, Istvan ;
Kovacevic, Zoran ;
Lesovoy, Vladimir ;
Schmidt-Wolf, Ingo G. H. ;
Barbarash, Olga ;
Gokmen, Erhan ;
O'Toole, Timothy ;
Lustgarten, Stephanie ;
Moore, Laurence ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281
[10]   Vascular endothelial growth factor-D and its receptor VEGFR-3:: Two novel independent prognostic markers in gastric adenocarcinoma [J].
Jüttner, S ;
Wissmann, C ;
Jöns, T ;
Vieth, M ;
Hertel, J ;
Gretschel, S ;
Schlag, PM ;
Kemmner, W ;
Höcker, M .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :228-240